Innovent Biologics’ Post

Excited to share our latest systematic review on the impact of SGLT2 inhibitors on kidney function in Muslim patients with type 2 diabetes during Ramadan. Our analysis of studies from 2013-2023 found that SGLT2 inhibitors do not significantly alter eGFR, suggesting their safety for use during fasting. Read more in the full article: [https://lnkd.in/dEgH7E3a] #DiabetesResearch #RamadanFasting #SGLT2Inhibitors #KidneyFunction #SystematicReview

Up front & free to read in our Sept issue #editorspicks: Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial tinyurl.com/594yrmez

Why C-Peptide Test is mportant iin Diabetes 🌟 Join us in this informative video as we delve into the importance of C-peptide testing for diabetes management. Learn how this test measures insulin production in the body and why it's crucial for diagnosing diabetes type and monitoring treatment effectiveness. The C-peptide test plays a vital role in monitoring diabetes treatment effectiveness by assessing the body's insulin production.

Results directly informed the recommendations of the 2023 International #PCOS Guideline 🔗 https://lnkd.in/e_zirmTC 👉 Oral glucose tolerance test is the optimal method for screening and diagnosing type 2 diabetes in women with PCOS and is superior to fasting plasma glucose and HbA1c. 📃 Diagnostic accuracy of oral glucose tolerance tests, fasting plasma glucose and haemoglobin A1c for type 2 diabetes in women with polycystic ovary syndrome: A systematic review and meta-analysis

Check out this Endpoints News article featuring our CSO, Steffen-Sebastian Bolz, MD, Ph.D., to learn more about the positive results from our Phase 2 study evaluating our lead candidate for the treatment of #prediabetes to help prevent the progression to type 2 diabetes: https://bit.ly/3xqFRNk

Metformin belongs to a class of drugs called biguanides it's indicated for: 1. Type 2 Diabetes Management 2. Gestational Diabetes 3. Prediabetes Prevention 4. Polycystic Ovary Syndrome (PCOS) 5. Helps in Trastuzumab induced cardiomyopathy

The FDA recently approved the first drug for advanced liver disease! The daily pill Rezdiffra is the first treatment for people with a type of liver disease known as MASH, which affects up to 20% of people with type 2 diabetes. Rezdiffra’s approval marks a big step forward for the treatment of liver disease related to metabolic dysfunction. For the first time, people with moderate to advanced liver disease have a daily pill option to help resolve MASH and liver scarring. To learn more about Rezdiffra, visit: bit.ly/4fc2hTK #myAMCR #HeadlandsResearchAMCR #LiverDisease #DiabetesAndLiverDisease #Type2Diabetes #DrugDevelopment #Rezdiffra

CAPRILCARE (Captopril)is an angiotensin-converting enzyme (ACE) inhibitor medication used to treat various cardiovascular conditions, including: 1. Hypertension (high blood pressure) 2. Heart failure 3. Left ventricular dysfunction after a heart attack 4. Diabetic nephropathy (kidney damage due to diabetes) Caprilcare works by: 1. Relaxing blood vessels, reducing blood pressure 2. Reducing the workload on the heart 3. Decreasing the production of fluids in the body, reducing swelling It is essential to consult with a healthcare professional before taking caprilcare, especially if you have a history of kidney disease, liver disease, or are taking other medications. Regular monitoring of blood pressure, kidney function, and potassium levels is crucial while taking caprilcare. #jaminpharm

Shining a spotlight on Sernova's pursuit of a functional cure for type 1 diabetes with their cell pouch technology. So far, five of the first six participants are insulin-independent. (The sixth participant has achieved "non-diabetic" blood sugar levels but still requires some insulin.) Their second cohort of seven participants is just getting started! Learn all about it right here: https://lnkd.in/gMAhvrA3